Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16523107 | 0.83 | HTT (0.41) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| Hydrochloric Acid SCHEMBL31531698 | 0.81 | HTT (0.40) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL502375 | 0.80 | HTT (0.39) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20808356 | 0.80 | HTT (0.39) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL13384283 | 0.80 | HTT (0.39) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL7260183 | 0.80 | HTT (0.39) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL7256301 | 0.79 | FGFR1 (0.38) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30871722 | 0.78 | ALDH1A1 (0.40) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL7261739 | 0.78 | HTT (0.37) | HTTFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL502126 | 0.76 | HTT (0.36) | HTTFGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132126-A1 | IMIDAZOLE DERIVATIVES | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4603489-A1 | IMIDAZOLE DERIVATIVE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2025-08-20 | — | — | EP | disclosed |
| CN-119998277-A | Imidazole derivatives | 株式会社三和化学研究所 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024080361-A1 | IMIDAZOLE DERIVATIVE | 株式会社 三和化学研究所 | 2024-04-18 | — | — | WO | disclosed |
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-5096915-A | For phytopathogens | SCHERING AGROCHEMICALS (GB) | 1992-03-17 | — | — | US | disclosed |
| EP-0390506-A1 | Azole fungicides | AgrEvo UK Limited (GB) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | HTT 283/4885SORD 977/4885FGFR1 2337/4885 |
| US-20260132126-A1 | IMIDAZOLE DERIVATIVES | ADRA1A, ADRA1D, ADRB1 | HTT 4347/4885SORD 2165/4885FGFR1 500/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | HTT 283/4885SORD 977/4885FGFR1 2337/4885 |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | NQO1, NDC1, NTPCR | HTT 316/4885SORD 517/4885FGFR1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.